COMPLEX SYSTEMS APPROACH TO MODELING FOLATE METABOLISM:
EXAMINING THE HOMOCYSTEINE REMETHYLATION PATHWAY

A Dissertation
Presented to the Faculty of the Graduate School
of Cornell University
In Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy

by
Xuan-Mai Teresa Nguyen
January 2014
The overall objective of this research is to examine the joint effect of multiple variants in folate metabolism on CVD outcome. The intermediary outcome, homocysteine, will be investigated as the primary endpoint because the metabolic disruption characterized by elevated homocysteine levels is proposed to mediate the risk of CVD. Because epidemiologic studies are limited by small sample size, and thus reduced statistical power to examine genetic interactions and their combined effects on disease outcome, we utilize computer simulations to study five SNPs in four candidate genes that code for enzymes that are all linked through sequential metabolic steps in homocysteine remethylation. These enzymes are either directly involved in homocysteine remethylation or indirectly linked because they provide essential substrates required for the conversion of homocysteine to methionine by MTR. Using MTR as our focal point, we also considered gene-nutrient interactions among the five variants and varying levels of folate and vitamin B12 to account for the possible effects of nutritional status on disease risk. This approach led to the key finding that having double variants for all possible polymorphisms in a pathway does not necessarily equate to the most deleterious effects, and that only vitamin B12 had an effect on the homocysteine levels as a nutrient cofactor. Our simulations also illustrate how pathways have built-in regulatory mechanisms that researchers might not be able to account for when taking a single candidate gene approach to studying disease
outcome. We anticipate that our model will serve as an example of how simulations can help advance the growing idea that disease treatment can be personalized by examining an individual’s unique genetic and nutritional profile.
BIOGRAPHICAL SKETCH

Xuan-Mai Nguyen was born to Canh Minh Nguyen and Ngoc-Nhung Viec in 1984 in the United States. She received her undergraduate degree in Applied Mathematics with an emphasis in Biostatistics at the University of California, Berkeley in 2004. Immediately following graduation, she began work on her M.S. and Ph.D. in Human Nutrition at the Division of Nutritional Sciences at Cornell University. For her Ph.D., she has minored in the fields of Biomedical Engineering and Genomics and has attended classes at the New England Complex Systems Institute in Cambridge, MA to further her training in modeling human metabolic pathways using a complex systems approach.
Dedicated to Bó, Mẹ, Nam and Bác Anh Teo–I’m finally done!
ACKNOWLEDGMENTS

This work would not have been possible without the understanding and amazing mentorship of Dr. Virginia Utermohlen, my Ph.D. advisor. She has provided the best combination of attentive listening, moral support and academic guidance throughout my graduate career. Her constant support has given me the opportunity to finally bridge my background in mathematics with my passion for understanding nutrition and disease. Dr. U’s flexibility and faith in my abilities as a researcher and as an aspiring physician has been invaluable. I hope that I have not disappointed her!

I stumbled into your graduate BME class by accident, but I have never regretted taking your course or having you as my mentor, Dr. Peter Doerschuk. Your help during my journey to complete this dissertation has been incredible, and despite my rather scenic route through graduate school, I have finally arrived at my destination thanks to your encouragement and constant support.

Members of my graduate committee, Dr. Timothy O’Brien, Dr. David Lin and Dr. Zhenglong Gu who have been essential in shaping and inspiring the ideas presented in this dissertation.

My BSP family (John, Marco, Roger, Monica, Koy) and Maureen Lahiff at UC Berkeley for encouraging me to find my passion and to embark on this journey.
<table>
<thead>
<tr>
<th>TABLE OF CONTENTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Biographical Sketch</td>
<td>iii</td>
</tr>
<tr>
<td>Dedication</td>
<td>iv</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>v</td>
</tr>
<tr>
<td>Chapter 1: Theoretical Motivation</td>
<td>1</td>
</tr>
<tr>
<td>Chapter 1A: Folate Metabolism and Cardiovascular Disease</td>
<td>1</td>
</tr>
<tr>
<td>Chapter 1B: Complex Systems Methods</td>
<td>14</td>
</tr>
<tr>
<td>Research Significance and Objectives</td>
<td>22</td>
</tr>
<tr>
<td>Chapter 2: Modeling Algorithm and Program</td>
<td>24</td>
</tr>
<tr>
<td>Chapter 3: Findings and Conclusions</td>
<td>40</td>
</tr>
<tr>
<td>Appendix</td>
<td>46</td>
</tr>
<tr>
<td>Appendix A1: ODE Annotated Matlab Program</td>
<td>46</td>
</tr>
<tr>
<td>Appendix A2: RHS Annotated Matlab Program</td>
<td>50</td>
</tr>
<tr>
<td>Appendix A3: V_Enzyme Annotated Matlab Program</td>
<td>52</td>
</tr>
<tr>
<td>Appendix A4: Combo_Effect Annotated Matlab Program</td>
<td>56</td>
</tr>
<tr>
<td>Appendix A5: Simulation Results for All Polymorphism and Nutrients</td>
<td>59</td>
</tr>
<tr>
<td>References</td>
<td>182</td>
</tr>
</tbody>
</table>
LIST OF FIGURES

Figure 1.1: Overview of Homocysteine Metabolism 2
Figure 1.2: Homocysteine Remethylation through the MTR Pathway 3
Figure 1.3: Global Folate Metabolic Network 5
Figure 1.4: Multilevel-ness in the study of cardiovascular disease 16
Figure 1.5: Coordination by a Coordination Process 19
Figure 2.1: Folate and Methionine Cycle 25
Figure 2.2: Flow Chart of Order of Program Processes 39
LIST OF TABLES

Table 1.1: Five Gene and SNP Information 13
Table 2.1: Concentrations of Substrates Used in Model 26
Table 2.2: Initial Substrate Concentrations Used in Model 27
Table 2.3: Kinetic Parameter Values Used in Model 29
Table 2.4: List of Functional Effects on Enzyme Activity 35
Figure 2.1: Folate and Methionine Cycle 25
Figure 2.2: Flow Chart of Order of Program Processes 39
CHAPTER 1
THEORETICAL MOTIVATION FOR COMPLEX SYSTEMS MODELING OF METABOLIC PATHWAYS

A. FOLATE METABOLISM AND CARDIOVASCULAR DISEASE

Cardiovascular disease

Cardiovascular disease (CVD) is the leading cause of adult morbidity and mortality worldwide, and is expected to remain as the primary cause of death through the year 2030 (1-2). The most common forms of CVD are multifactorial in origin, resulting from single or many genes working in combination with other genes (i.e. gene-gene interactions) and/or environmental factors to produce CVD risk (3). Monogenetic CVD can also arise due to a single genetic mutation in one of three genes involved in lipoprotein synthesis, but such incidences are rare (3-5). “Classical” risk factors for CVD are age, male gender, family history of premature CVD, cigarette smoking, hypertension, lipid abnormalities, diabetes mellitus, physical inactivity, poor diet, alcohol intake and obesity (6). Recently, other risk markers thought to play a causal role in CVD development have been identified, including biochemical indicators such as elevated plasma homocysteine (7).

Homocysteine: a biomarker for CVD

Homocysteine is a sulfur amino acid that forms as a result of S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) demethylating the essential amino acid methionine (8). Total plasma homocysteine, which refers to all forms of homocysteine in plasma (i.e., free form or protein-bound (majority)), can be metabolized via two separate pathways: the irreversible transsulfuration pathway and the homocysteine remethylation pathway; the latter predominates under normal physiological conditions (9-10) (Figure 1.1).
Figure 1.1: Overview of Homocysteine Metabolism

Major enzymes, nutrient cofactors and their roles in homocysteine remethylation:
MAT = methionine adenosyltransferase; MT = methyltransferases; SAHH = S-adenosylhomocysteine hydrolase; BHMT = betaine-homocysteine methyltransferase;
MTHFD = methylenetetrahydrofolate dehydrogenase; SHMT = serine hydroxymethyltransferase; CBS = cystathionine beta-synthase; C = gamma-cystathionase; MTR = methionine synthase; MTHFR = methylenetetrahydrofolate reductase; THF = tetrahydrofolate; B2, B6, B12 = vitamins B2, B6, B12, respectively.
Degradation of intracellular homocysteine to cysteine through the transsulfuration pathway is limited to liver and kidney cells and involves cystathionine beta-synthase (CBS) and γ-cystathionase, enzymes that both require pyridoxal 5’-phosphate (PLP; vitamin B6) as a cofactor while homocysteine remethylation occurs through two unique enzymatic reactions involving either methionine synthase (MTR) with 5-methyltetrahydrofolate (5-methylTHF) as the methyl donor or betaine-homocysteine methyltransferase (BHMT) with betaine as the donor of one-carbon units. Remethylation by BHMT is restricted to liver and kidney cells while remethylation by MTR can occur in every cell except red blood cells (8-10). The primary focus of this research is directed towards understanding the role of key factors involved in homocysteine remethylation through the MTR pathway where MTR is the major transmethylase (Figure 1.2).

**Figure 1.2: Homocysteine Remethylation through the MTR pathway**

MTHFD = methylenetetrahydrofolate dehydrogenase; SHMT = serine hydroxymethyltransferase; MTR = methionine synthase; MTHFR = methylenetetrahydrofolate reductase; THF = tetrahydrofolate
Epidemiology of CVD

Studies taking the traditional reductionist approach have concluded that disruption of normal enzymatic function within the homocysteine remethylation pathway through MTR can result in an accumulation of homocysteine, leading to increased CVD risk. Meta-analyses of epidemiologic studies have found that total plasma homocysteine is an independent predictor of CVD (11-12). Results from a meta-analysis conducted in 2002 of prospective studies estimated that a decrease in total plasma homocysteine of 3umol/L was associated with a 16% decrease in heart disease (12). Similarly, a meta-analysis by the Homocysteine Studies Collaboration that included studies published between January 1966 and January 1999 reported that a 25% lower than usual homocysteine level (~3 umol/L; 0.41mg/L) was associated with an 11% lower risk of ischemic heart disease (OR= 0.89; 95% CI: 0.83-0.96) (11). The mechanisms by which elevated homocysteine affects CVD risk are not completely specified, but it has been hypothesized that elevated homocysteine concentrations cause: (a) endothelial dysfunction by impairing nitric oxide synthesis (b) platelet activation, (c) a pro-inflammatory response by inducing production of tumor necrosis factor-alpha and (d) accelerated oxidation of low-density lipoproteins (LDL), and thus, atherosclerosis (6,7,10-11, 13-24). The proposed mechanisms by which homocysteine increases CVD risk support epidemiologic findings that report an association between increased blood homocysteine concentrations among individuals with vascular disease, where elevated homocysteine levels precede CVD onset (25-29).

Genetic and Nutritional Determinants of Homocysteine Remethylation and CVD Risk

The homocysteine remethylation pathway via MTR is embedded within the larger one-carbon folate metabolic pathway (Figure 1.3). Studies have demonstrated an association between increased blood homocysteine concentrations and changes in individual states of oxidation as well as the addition or removal of one-carbon groups.
like folate (30). MTR, a vitamin B12-dependent enzyme, catalyzes the methyl group transfer from 5-methylTHF to homocysteine, resulting in methionine and THF (31). The proper functioning of this enzyme is critical for ensuring that homocysteine levels do not reach toxic levels. It is, thus, biologically plausible that inadequate levels of vitamin B12 or disruption in MTR function can affect MTR activity level, which in turn can lead to hyperhomocysteinemia as well as homocysteinuria (32).

Figure 1.3: Global Folate Metabolic Network, adapted from Stipanuk et al. (33)
These are the major folate-dependent one carbon metabolic pathways in the cytoplasm of the cell. AICAR: 5-amino-4-imidazolecarboxamid ribonucleotide; AICART: AICAR formyltransferase; CYH: methenyltetrahydrofolate cyclohydrolase; DHFR: dihydrofolate reductase; dTMP: 2-deoxythymidine 5’-monophosphate; dUMP: 2-deoxyuridine 5’-monophosphate; GAR: glycaminide ribonucleotide; GART: GAR formyltransferase; MS (MTR): methionine synthase; MTHFD: methylenetetrahydrofolate dehydrogenase; MTHFR methylenetetrahydrofolate reductase; (c)SHMT: cytoplasmic serine hydroxymethyltransferase; TS: thymidylate synthase.
A common single nucleotide polymorphism (SNP) in \textit{MTR} consists of an A-to-G nucleotide substitution at base pair 2756 (rs1805087), leading to an amino acid change from aspartic acid to glycine at codon 919 (34). Functional consequences of this mutation have not been clearly established, and the influence of the \textit{MTR} 2756 A$\rightarrow$G polymorphism on total plasma homocysteine levels is still a matter of debate. Some studies suggest that individuals with \textit{MTR} 2756 AA genotype have lower homocysteine concentrations (compared to those with \textit{MTR} 2756 GG genotype), implying an increased level of enzymatic activity in the presence of the variant genotype (35-38). Other studies have reported either no functional differences (39-42) or an increase in homocysteine concentration as a result of the \textit{MTR} 2756 A$\rightarrow$G polymorphism (37, 43). In laboratory studies, complete loss of MTR activity in mice has been linked to early embryonic lethality (44). Similarly, severe clinical consequences have been observed in humans lacking MTR activity (45).

With regard to nutrient cofactors, traditional gene association studies hypothesize that the \textit{MTR} 2756 A$\rightarrow$G polymorphism may decrease the ability of vitamin B12 to bind to its receptor site on MTR, in part because the SNP is in close proximity to the vitamin B12 binding domain of the protein. The role of vitamin B12 as a cofactor is critical for proper MTR function because it serves as an intermediary in methyl transfers catalyzed by MTR (46). Thus, the SNP is hypothesized to increase the risk of CVD (less remethylation of homocysteine) as well as increase cellular B12 levels (less binding of B12 to enzyme). With respect to plasma vitamin B12 levels, prior work has shown that reduced levels of plasma vitamin B12 are associated with higher homocysteine levels and thus, greater CVD risk (47). Typically about 20% of total circulating vitamin B12 is carried by transcobalamin 2, which is responsible for transporting vitamin B12 in the blood to the cell, and a reduction in total circulating vitamin B12 levels will proportionally reduce the availability of vitamin B12 to bind
to transcobalamin 2, causing a deficit in vitamin B12 availability for MTR to use as a cofactor to remethylate homocysteine. Studies examining the association of $MTR\, 2756\, A\rightarrow G$ with circulating vitamin B12 levels have produced mixed results: some report no association between $MTR\, 2756\, A\rightarrow G$ genotype and blood vitamin B12 levels (37, 41, 48-49) and others report a decrease of ~30% in serum vitamin B12 levels by $MTR\, 2756\, A\rightarrow G$ genotype ($MTR\, 2756\, GG$ vs. $MTR\, 2756\, AA/AG$) (40, 50). To the best of our knowledge, whether the effect of the polymorphism on cardiovascular disease risk varies by nutritional status of vitamin B12 has not been studied to date. However, results from animal studies support the idea that vitamin B12 concentration plays a critical role in stabilizing MTR activity as induced B12-deficient rats had severely reduced MTR activity levels compared to the enzyme activity levels of rats in a control group who were not B12-deficient (51).

Homocysteine remethylation by MTR also requires 5-methylTHF as a substrate, which is provided by a reaction catalyzed by methylenetetrahydrofolate reductase (MTHFR). This key enzyme has been extensively studied in relation to CVD pathogenesis because MTHFR is responsible for the reduction of 5,10-methylenetetrahydrofolate (5,10-methyleneTHF) to 5-methylTHF, the active folate derivative required for homocysteine remethylation. Insufficient levels of this major form of folate in the human body can result in hyperhomocysteinemia (52-53). A single base, non-synonymous substitution of C to T at nucleotide 677 (rs1801133), leading to an alanine to valine amino acid substitution at codon 222, has been identified where a missense mutation in the region encoding the N-terminal catalytic domain results in a thermolabile variant with a 50% reduction in enzymatic activity (54-55). This variant has been consistently associated with mildly elevated plasma homocysteine levels (52, 56) and has been found to be more prevalent among individuals with CVD than those without (55, 57). Given that $MTHFR\, 677\, C\rightarrow T$ is
the most widely studied polymorphism in folate metabolism, we seek to understand how the combined effects of other polymorphisms affecting enzymes in folate metabolism influence the relation of $MTHFR$ 677 $C\rightarrow T$ with elevated homocysteine levels.

The thermolabile $MTHFR$ 677 $C\rightarrow T$ polymorphism accounts for mild hyperhomocysteinemia in only about 25% of vascular disease patients (52), suggesting that additional mutations in the $MTHFR$ gene, or in related genes, may contribute to elevated homocysteine levels. One such polymorphism found in the C-terminal regulatory domain of MTHFR is $MTHFR$ 1298 $A\rightarrow C$ (rs1801131), which leads to a glutamine to alanine amino acid substitution (54,58). Studies taking a single candidate gene approach have found no relation between the $MTHFR$ 1298 $A\rightarrow C$ polymorphism, homocysteine levels and risk for CVD (59-62). However, results from observational studies looking at the combined effects of $MTHFR$ 1298 $A\rightarrow C$ and $MTHFR$ 677 $C\rightarrow T$ have produced mixed results: several studies reported no additional explanatory power in $MTHFR$ 1298 $A\rightarrow C$ for predicting coronary disease outcome once the $MTHFR$ 677 $C\rightarrow T$ SNP was considered (59-62), but other reports suggest that combined heterozygosity for $MTHFR$ 677 $C\rightarrow T$ and $MTHFR$ 1298 $A\rightarrow C$ mutations is associated with hyperhomocysteinemia (58). More specifically, van der Put et al. examined the effects of $MTHFR$ 1298 $A\rightarrow C$ on homocysteine levels and CVD risk and demonstrated an interactive effect: individuals heterozygous for both $MTHFR$ 677 $C\rightarrow T$ and $MTHFR$ 1298 $A\rightarrow C$ had reduced MTHFR specific activity (ANOVA p<0.0001), higher homocysteine levels and decreased plasma folate levels (ANOVA p<0.03) (58). The effect of combined heterozygosity was also shown by Lievers et al. and Weisberg et al. who noted that individuals with $MTHFR$ 677 $CT/1298 AC$ genotype had slightly higher homocysteine levels than those with the $MTHFR$ 677 $CT/1298 AA$ genotype (54, 63-64). When folate status was additionally
accounted for, Weisberg et al. found that the relation between MTHFR 1298 A→C genotype and homocysteine levels was stronger among those with folate levels below the median than those with levels above the median, though the association was not statistically significant (data not shown in publication) (54). Finally, an in vitro study directly assessing the effect of MTHFR 1298 A→C on enzyme activity and thermolability concluded that the MTHFR 677 C→T variant was more deleterious than the alanine variant of MTHFR 1298 A→C (54), suggesting that the role of MTHFR 1298 A→C on MTHFR enzyme activity is minor compared to that of MTHFR 677 C→T. Overall, the evidence to date is suggests that the effect of MTHFR 1298 A→C is not observed to have an effect on clinical outcomes unless there is a reduced folate status or there is also a variant allele at the 677 nucleotide (MTHFR 677 C→T). In our current study, a mathematical model including both MTHFR SNPs will allow for a complete examination of the MTHFR genotype combinations as they relate to homocysteine levels.

In addition to genetic factors, MTHFR activity is also influenced by levels of folate. Epidemiology studies have found that in populations with low folate status the associations among the MTHFR 677 C→T polymorphism, CVD risk, and elevated homocysteine are more pronounced (53, 65). However, when folate levels are higher, the net effect of the MTHFR 677 C→T polymorphism on homocysteine levels is attenuated (65), highlighting an important gene-nutrient interaction between folate and MTHFR 677 C→T.

The rate of conversion of 5,10-methyleneTHF to 5-methylTHF, which is needed for homocysteine remethylation by MTR, is also dependent on the availability of 5,10-methyleneTHF. Cytosolic serine hydroxymethyltransferase (cSHMT) and methylenetetrahydrofolate dehydrogenase (MTHFD1) are both enzymes that catalyze reactions producing 5,10-methyleneTHF. Metabolic disruptions caused by changes in
activity in these enzymes make cSHMT and MTHFD1 important producers of a substrate that may ultimately influence homocysteine remethylation. cSHMT is a key enzyme responsible for regulating and maintaining the homeostasis of the intracellular one-carbon pool. It supplies one-carbon units for thymidylate biosynthesis, sequesters 5-methylTHF causing reduced S-adenosylmethionine synthesis, and catalyzes glycine-dependent serine synthesis which depletes 5,10-methyleneTHF for homocysteine remethylation (66).

A SNP in cSHMT, cSHMT 1420 C→T, was identified by Stover et al., and causes an amino acid change from leucine to phenylalanine (67-68). Recent studies find that cSHMT 1420 C→T polymorphism (rs1979277) is located close to the sumoylation site on the cSHMT protein, which affects nuclear localization of the protein (69). Epidemiologic studies have implicated this polymorphism in a variety of diseases including leukemia (70) and lymphoma (71-72), esophageal squamous cell carcinoma and gastric cardia adenocarcinoma (73) and neural tube defects (74). cSHMT 1420 C→T has also been investigated in relation to CVD outcome: findings show that the effect of MTHFR 677 C→T on CVD risk is strongly influenced by cSHMT 1420 C→T genotype. Specifically, among men with cSHMT 1420 TT genotype, the risk of CVD for MTHFR 677 CT and TT genotypes was 3.6 (95% CI: 1.7,7-8) and 10.6 (95% CI: 2.5, 46.0), respectively (compared to MTHFR 677 CC genotype). Among men with cSHMT 1420 CC/CT genotype the risk for CVD among MTHFR 677 CT and TT genotypes (compared to MTHFR 677 CC) was 1.0 (95% CI: 0.8, 1.2) and 1.3 (95% CI: 0.9, 1.8), respectively (75). Whether this increase risk is a result of elevated homocysteine levels was not determined.

This evidence suggests that the metabolic disruptions resulting from cSHMT 1420 C→T have the potential to play a role in health outcomes, particularly in CVD pathogenesis, through gene-gene interactions. Since the study by Lim et al. (75) found
an effect resulting from a pair-wise interaction between polymorphisms in \textit{cSHMT} and \textit{MTHFR} on CVD risk, it is plausible that these polymorphisms may also interact with SNPs in \textit{MTR} or \textit{MTHFD1} from the epidemiology perspective. Again, the relationship of any clinical consequence to hyperhomocysteinemia remains unknown.

\textit{MTHFD1} is a tri-functional enzyme that catalyzes three sequential reactions responsible for the interconversion of 5,10-methyleneTHF and THF. A polymorphism in the coding region, \textit{MTHFD1} 1958 \textit{G}\text{→}A (R653Q; rs2236225) has been implicated as a cause of neural tube defects (76-77), bipolar disorder and schizophrenia (78) and is associated with the risk for migraine and gastric cancer through an interaction with the \textit{MTHFR} 677 \textit{C}\text{→}T genotype (79-80). Because \textit{MTHFD1} provides the essential substrate for \textit{MTHFR}, mutations in the \textit{MTHFD1} gene that affect enzyme activity are hypothesized to influence levels of homocysteine, and consequently, CVD risk. Only one study has examined the effects of \textit{MTHFD1} 1958 \textit{G}\text{→}A and \textit{MTHFR} 677 \textit{C}\text{→}T on CVD risk (Raiszadeh, personal communication). Findings suggest that \textit{MTHFD1} \textit{GA}/\textit{AA} (vs. \textit{MTHFD1} \textit{GG}) had a statistically non-significant protective association with CVD risk (OR 0.8; 95% CI 0.6, 1.1), and this association was similar across folate subgroups. A gene-gene interaction was observed whereby an increased risk of CVD was found for the \textit{MTHFR} 677 \textit{TT} genotype (vs. \textit{MTHFR} 677 \textit{CC}), but only among men with \textit{MTHFD1} \textit{GA}/\textit{AA} genotype (OR 1.6, 95% CI 1.1, 2.4). Similarly, the \textit{MTHFR} 677 \textit{CT} genotype (vs. \textit{MTHFR} 677 \textit{CC}) increased CVD risk among men with \textit{MTHFD1} \textit{GA}/\textit{AA} genotype (OR 1.2; 95% CI 0.9, 1.7), but had little or no effect in men with the \textit{MTHFD1} \textit{GG} genotype (OR 0.8; 95% CI 0.5, 1.3) (Raiszadeh, personal communication). No other study to date has examined the role of multiple polymorphisms that include \textit{MTHFD1} 1958 \textit{G}\text{→}A on CVD risk by examining the changes in homocysteine levels.
Taking a new approach to understanding cardiovascular disease, the research presented in the following chapters examines the interactive effect of 5 SNPs in genes coding for enzymes in folate metabolism on CVD outcome by looking at changes in homocysteine steady state concentrations as a proxy (Table 1.1). To the best of our knowledge, no published study to date has considered more than one gene-gene interaction in genes within the homocysteine remethylation pathway in relation to CVD outcome. Moreover, the majority of studies to date have taken an epidemiologic approach to understanding folate metabolism and its relation to homocysteine and cardiovascular disease. While epidemiologic gene association studies help identify correlations between single genetic variables and disease outcomes, such an isolated approach rarely leads to the formulation of relations that can remain true when entities of a biological system are examined as a whole with respect to disease outcome. Thus, to understand how genetic polymorphisms affect enzymes in homocysteine remethylation as a whole, we propose a new method of analyzing biological systems using complex systems analysis.
<table>
<thead>
<tr>
<th>Gene</th>
<th>SNP</th>
<th>Amino Acid Change</th>
<th>MAF$^1$</th>
</tr>
</thead>
<tbody>
<tr>
<td>cSHMT</td>
<td>1420 C→T</td>
<td>Leu474Phe</td>
<td>HapMap CEU: 0.333</td>
</tr>
<tr>
<td>17p11.2$^2$</td>
<td>rs1979277</td>
<td></td>
<td>NAS: 0.310</td>
</tr>
<tr>
<td>MTHFD1</td>
<td>1958 G→A</td>
<td>Arg653Gln</td>
<td>HapMap CEU: 0.458</td>
</tr>
<tr>
<td>14q24</td>
<td>rs2236225</td>
<td></td>
<td>NAS: 0.465</td>
</tr>
<tr>
<td>MTHFR</td>
<td>677 C→T</td>
<td>Ala222Val</td>
<td>HapMap CEU: 0.242</td>
</tr>
<tr>
<td>1p36.3</td>
<td>rs1801133</td>
<td></td>
<td>NAS: 0.363</td>
</tr>
<tr>
<td></td>
<td>1298 A→C</td>
<td>Glu429Ala</td>
<td>HapMap CEU: 0.358</td>
</tr>
<tr>
<td></td>
<td>rs1801131</td>
<td></td>
<td>NAS: 0.306</td>
</tr>
<tr>
<td>MTR</td>
<td>2756 A→G</td>
<td>Asp919Gly</td>
<td>HapMap CEU: 0.167</td>
</tr>
<tr>
<td>1q43</td>
<td>rs1805087</td>
<td></td>
<td>NAS: 0.181</td>
</tr>
</tbody>
</table>

$^1$Minor Allele Frequency for each of the 5 SNPs assayed in the Normative Aging Study population (NAS), which consists of white males with European ancestry, compared to the CEU reference population, which refers to the subgroup of people living in Utah with ancestry from northern and western Europe in the International Haplotype Mapping (HapMap) Project (81)

$^2$Chromosome location
B. THE ROLE OF COMPLEX SYSTEMS METHODS IN METABOLIC MODELING

*Systems Biology and Complex Systems Approach*

The discipline of systems biology focuses on addressing the great intellectual and technical challenges associated with translating genome sequence into a comprehensive understanding of how organisms are built and run. It is rooted in the idea organisms are more than the sum of their parts, and the behavior of their physiological processes cannot be understood by simply knowing how the parts work in isolation. A systems level characterization of a biological process addresses three fundamental questions: (i.) what are the parts of the system? (i.e., the genes and the enzymes and proteins that they code); (ii.) how do the parts work? (iii.) how do the parts work together to complete a task? (82).

A system is a relation of items. Items within a system take on any range of identities including physical objects, indicators, variables or even symbols. For example, a genome is a set of genes and a metabolic pathway can be described by rate equations. In mathematical set theory, a system can be defined as the set of all ways in which an item A, can be found in the system, where * denotes that all items are seen simultaneously.

\[ S \subset A_1 * A_2 * \ldots * A_i * \ldots * A_n \]

Here, an element of S represents a multiple of the elements in each of the items, \( s = (i_1, \ldots, i_n) \). Items are mutually interdependent, therefore, they constitute a relation.

A complex system is therefore defined by the following: (i.) the global system has a distinct behavior and (ii.) the subsystems within the global system preserve their own identities and inherent properties. Symbolically, a complex system can be represented as:

\[ S \subset S_1 * S_2 * \ldots * S_i * \ldots * S_n \]
In describing a complex system, “distinct” behaviors imply that the behavior of the complex overall system is described in terms of items (i.e., subsystems) that are different than the items used to describe the subsystem components. For example, Figure 1.3 illustrates the folate metabolic network, an entity that can be considered as a global system. Here, there are three subsystems that describe the global system: the methionine cycle, thymidylate cycle and the purine cycle. Furthermore, each subsystem is characterized by items such as enzyme kinetics, substrate concentration, product concentration and nutrient cofactor levels. Figure 1.1 illustrates the items for describing the methionine cycle subsystem. The items used to describe the subsystems that form a complex system have their own boundaries and existence, yet their behavior and function is conditioned by their presence within the overall global, complex system. Specifically, the methionine cycle, thymidylate cycle and purine cycle are all acknowledged as such, but their functioning and existence is conditioned as being part of the total system (i.e., folate metabolism).

*Principles of organized complexity*

A major challenge that has yet to be fully addressed in systems biology is the development of principles of organized complexity in biological systems. These principles, in theory, should provide a starting framework to uncover the understanding of systems from observation and data. Moreover, these principles should indicate the functions of biological systems and/or their components. They provide the “architecture” of the model and may not necessarily be numerically based.

*Levels of complexity and the autonomy of levels*

The idea of multilevel-ness is an essential principle of organized complexity. A biological example of multilevel-ness can be seen in the study of CVD. CVD is a complex event that can be studied from a variety of perspectives. Genetic variables, small molecule and protein interactions as well as epidemiological trends are viable
methods of studying CVD. Each method provides a subset of information explaining some aspect of CVD. How all of the subsets can be combined or studied concurrently to provide an understanding at the global level lies at the heart of systems biology from a complex systems approach. The concern in systems biology and complex systems is, therefore, to understand how the functioning of a higher level (i.e., the global level) is related to the functioning on a lower level (Figure 1.4).

**Figure 1.4: Multilevel-ness in the study of cardiovascular disease**
The study of complex systems is “a new field of science studying how parts of a system give rise to the collective behaviors of the system, and how the system interacts with it environment…It focuses on certain questions about parts, wholes and relationships…[It] is about understanding indirect effects” (83). Complex systems, therefore, is integrative and seeks to understand and predict the behavior or “emergent” properties of complex, multicomponent biological processes. Here, emergent is defined as the distinct behavior on a higher level that is solely due to the way the subsystems on the lower functioning level interact.

As Stuart Kauffmann suggested, there are domains of autonomy on the lower level of subsystems that do not affect the behavior of the system at the higher level. The domain of autonomy is a range of changes on the lower level and the corresponding range of normal behavior on the higher level such that the two levels do not interact; the changes on the functional level are treated as “background noise” on the higher level (84). This brings up the need to clarify the idea of interaction and interdependence among levels and subsystems within a complex system, namely, that even though levels are interdependent in many ways, they can be viewed as non-interacting within domains of autonomy. In the case of folate metabolism, all three subsystems (i.e., methionine, thymidylate and purine cycles) are all interdependent on each other via 5,10-methylenetetrahydrofolate. While enzymes and cofactors in each cycle will perturb reaction rates and equilibrium within their respective cycles, whether or not these perturbations of the “subsystems” are manifested in the global properties that drive folate metabolism is best measured using a complex systems approach.

*Interactions and Links*

When a system is “complex,” its subsystems and items defining each subsystem are interdependent and a quantifiable description of each item of varying levels requires
algorithmic complexity. Algorithmic complexity, is defined as the quantity of items needed to describe the system (or subsystem) and the number of clauses to define the relationships/interactions among the items is large (i.e., it cannot be described with a single-worded answer or using a single sentence). The descriptions for items at each level vary. At the higher level, the purpose is to coordinate the subsystems to perform work. Thus, the function of interactions at the higher level should consist of providing guidance or motivation for the subsystems to act so as to advance the overall system’s objective. It is necessary to organize the functioning of subsystems so that the overall system, as a whole, functions properly (84). In the case of folate metabolism, this means that at the higher level of complexity, the folate metabolic system, as represented in Figure 1.5 as CP(Δp), is concerned with ensuring that thymidylate, methionine and purine cycles (S[Δi(β)], where Δ1…Δn represent regulation objectives) are all operating such that folate metabolic system will continue to function. Coordination theory (85) suggests that coordination can affect the first level of subsystems (i.e., the three cycles) by an input β to modify their functioning. These three subsystems are, in turn, responsible for their own functions at a lower level (i.e., regulating their enzymes/items) and are modified by coordination at the higher level.

In other words, according to coordination theory, let Δ represent the functioning of the system as a whole and satΔ indicate that the functioning of the overall system is satisfactory. The purpose of the coordination task, Δp, is to influence all Δi(β) so that Δ is achieved while the first level systems (i.e., the subsystems) perform their own, first (lower) level functions where:

\[ \text{sat}\Delta_1(\beta) \cap \ldots \text{sat}\Delta_i(\beta) \cap \ldots \text{sat}\Delta_n(\beta) \cap \text{sat}\Delta_p \Rightarrow \text{sat}\Delta. \]
Figure 1.5: Coordination by a coordination process
S₁ is the first functional level subsystem; CP is the coordination process; Δ₀ is the coordination task; Δᵢ is the first level regulatory function; uᵢ is the interaction between subsystems; β is the coordination input
Coordination is also necessary if perturbations are made to the overall system. Such perturbations, denoted as \( x \), such as genetic mutations, can affect a subsystem’s ability to produce the correct amount and type (i.e., an enzyme) of information for the ideal, proper functioning of the overall system. When such a discrepancy arises, coordination is needed to bring equilibrium back to the coordination process and the system. Specifically, the coordination task, \( \Delta_p \), then has a purpose to find \( \beta \) such that the following holds true:

\[
[sat_{\Delta_1}(x,\beta) \cap \ldots sat_{\Delta_i}(x,\beta) \cap \ldots sat_{\Delta_n}(x,\beta)] \cap sat_{\Delta_p} \Rightarrow sat_{\Delta}.
\]

Sometimes, these perturbations cannot be corrected and a system’s equilibrium cannot be achieved. In this case, it is thought that over time, the system will adapt to reach a new state of equilibrium (85). More specifically, as with many biological phenomena, slight perturbations (i.e., single nucleotide polymorphisms) are often not fatal because biological systems are robust and resilient to change. This suggests that even with mutations, a biological system can tolerate deviations and imbalances and adapt within certain bounds to continue proper function at a reduced level of optimization. It is of interest to determine what these bounds are and how a system adapts. Using complex systems analysis, the bounds of a given metabolic pathways and perturbations within the pathway could theoretically be examined.

*Gene-Disease Modeling: A Case for the Complex Systems Approach*

Developing a systems level understanding of a physiological process requires identification of the genes and the proteins that they encode (i.e., the “parts”). The field of functional genomics is one that has developed and utilized large-scale and high-throughput methodologies to define and analyze gene function by integrating data obtained from multiple large-scale datasets (86-91). Traditional reductionism has also given us a deeper understanding of the parts involved in the organizational structure of biological processes. It has elucidated the importance of cellular
components and regulatory processes of specific genes, proteins and metabolites. In a sense, reductionism has established the foundation upon which the behavior of complex physiological processes can be studied as a whole.

As the writer Alvin Toffler once said, “One of the most highly developed skills in contemporary Western civilization is dissection: the split-up of problems into their smallest possible components. We are good at it. So good, we often forget to put the pieces back together again” (92). In the world of gene association studies, we see exactly what Toffler described, namely, we know a lot about the association of a single gene with a single disease outcome, but we fail to acknowledge the interdependency among different genes that code for enzymes and proteins that interact with one another (93).

Current strategies to understand the role of genetic variation in various clinical phenotypes illustrates the growing need for a complex systems approach to studying the relationship between genetic information and human disease. Original methodologies designed to discover links between genetic information and human disease have traditionally focused on the evaluation of candidate genes identified by classical reductionist techniques in the laboratory (94). This methodology relies on existing knowledge of the genes to determine the properties of important cell systems presumed to be disturbed in a disease state. Additionally, candidate gene studies have been characterized by the examination of genetic variation in a single gene, which ignores the interaction between related genes coding for proteins in the same pathway. Because investigation tends to be limited to genes of known function that have been linked to the pathophysiology of a disease in question, candidate gene studies can—and have- produced conflicting results. These inconclusive results are thought to be attributed to the fact that only select parts of a whole entity are studied; how can we possibly understand a whole system if we do not account for all of its parts? In
contrast, complex systems analysis would suggest that multiple genes are likely to play an important role in complex chronic diseases and that many “weaker” genes (i.e., those that may be insignificant when studied in isolation with respect to the disease) when combined, may actually have a contributing effect on disease risk or state (95).

**Research Significance and Objectives**

The overall objective of this study is to examine the joint effect of multiple variants in folate metabolism on CVD outcome. The intermediary outcome, homocysteine, will be investigated as the primary endpoint because the metabolic disruption characterized by elevated homocysteine levels is proposed to mediate the risk of CVD. Because epidemiologic studies are limited by small sample size, and thus reduced statistical power to examine genetic interactions and their combined effects on disease outcome, we use computer simulations to study five SNPs in four candidate genes that code for enzymes that are all linked through sequential metabolic steps in homocysteine remethylation. These enzymes are either directly involved in homocysteine remethylation or indirectly linked because they provide essential substrates required for the conversion of homocysteine to methionine by MTR. Using MTR as our focal point, we also considered gene-nutrient interactions among the five variants and varying levels of folate and vitamin B12 to account for the possible effects of nutritional status on disease risk. Such an approach allows for the consideration of multiple genotype-genotype interactions and multiple genotype-nutrient interactions, capturing the complexity underlying the development of CVD. The specific research aims are as follows:

1.) To examine the interactive effects of 5 SNPs on homocysteine levels and identify genetic profiles most susceptible to elevated homocysteine levels (and by extension, elevated risk for CVD);
2.) To determine how varying levels of 5-methyl-THF (folate) and vitamin B12, both required for MTR activity, affect homocysteine levels among the different genetic polymorphism combinations.
CHAPTER 2
MODELING ALGORITHM AND PROGRAM

This study utilizes mathematical modeling to understand the overall function of the folate metabolic network as it relates to homocysteine regulation through MTR. Vast amounts of scientific literature have provided extensive detail about single reactions and single pathways that comprise folate metabolism, but as previously discussed, no study has examined the overall function of homocysteine remethylation under the influence of multiple genetic variation and the possibility of further effects created by nutritional supplementation and variation. Due to limitations in statistical power (epidemiological studies) and levels of complexity that cannot be fully captured in purely experimental studies, we utilize mathematical models to study folate metabolism as a dynamic and complex biological system.

Basic Mathematical Model for Homocysteine Remethylation

To develop models of integrated biochemical processes, it is necessary to consider the mechanisms by which biochemical information is transferred in a network. In a mathematical model of folate metabolism created by Reed et al. (96), a model is derived using standard biochemical kinetics. It has been shown to reproduce both the many known properties of folate metabolism as well as the qualitative behaviors of the folate cycle reported in experimental studies (96-97).

In our study, the effect of multiple SNPs on homocysteine regulation via MTR (highlighted subsystem in Figure 2.1) was simulated by building upon the model of folate metabolism originally published by Reed et al. and Nijhout et al. (96-97). While our research focuses primarily on the highlighted subsystem within the larger folate metabolic system depicted in Figure 2.1, our mathematical model incorporates both the folate cycle and the methionine cycle in order to account for the presence of all folate-derived, intracellular substrates as well as folate regulating enzymes. Due to
limited information on all possible SNPs in genes coding for enzymes in the folate and methionine cycles, we have made some parameter and substrate values constant in our study and have focused primarily on genetic and nutrient outcomes related to genes and enzymes in our highlighted subsystem of interest. The values, expressed in micro Molar, μM, that we have kept constant are given in Table 2.1 and are based on information reported in the literature.

Figure 2.1: Folate and Methionine Cycle, adapted from Reed et al. (96). Substrates are represented by rectangular boxes, enzymes in ovals and vitamin cofactors in circles
Table 2.1: Concentrations of Substrates Used in Model that are held constant (units: µM)

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Concentration</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>glycine ribonucleotide [GAR]</td>
<td>10</td>
<td>98</td>
</tr>
<tr>
<td>aminoguanosidineribonucleotide [AICAR]</td>
<td>2.1</td>
<td>98-100</td>
</tr>
<tr>
<td>nicotinamide adenine dinucleotide phosphate [NADPH]</td>
<td>50</td>
<td>98,101</td>
</tr>
<tr>
<td>Glycine [GLY]</td>
<td>1850</td>
<td>98,99,102</td>
</tr>
<tr>
<td>Serine [SER]</td>
<td>468</td>
<td>98,99,102</td>
</tr>
<tr>
<td>Betaine [BET]</td>
<td>50</td>
<td>96</td>
</tr>
<tr>
<td>Formate [HCOOH]</td>
<td>500</td>
<td>100,102</td>
</tr>
<tr>
<td>Formaldehyde [H$_2$C = O]</td>
<td>500</td>
<td>96</td>
</tr>
<tr>
<td>deoxyuridine monophosphate [dUMP]</td>
<td>20</td>
<td>98-100</td>
</tr>
</tbody>
</table>

Our current model of the folate metabolic cycle is represented by ten differential equations and various enzyme velocity equations that describe folate substrate concentration over time. For each enzyme, the $K_m$ is given in µM and the $V_{max}$ and the enzyme velocities of the reactions, $V$, are expressed in µM/hr. The abbreviated notation used to describe our metabolic system is as follows:

5mTHF = 5-methyltetrahydrofolate  
THF = tetrahydrofolate  
DHF = dihydrofolate  
CH$_2$F = 5-10-methylenetetrahydrofolate  
CHF = 5-10-methenyltetrahydrofolate  
10fTHF = 10-formyltetrahydrofolate  
MET = methionine  
SAM = S-adenosylmethionine  
SAH = S-adenosylhomocysteine  
HCY = homocysteine  
Met$_{in}$ = influx of methionine into the system (µM/hr)  
F$_{in/out}$ = influx and outflux of folate
Initial concentrations for all variables in our model are given in Table 2 and are based on steady-state values found in the literature.

Table 2.2: Initial Substrate Concentrations Used in Models (units: µM)

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Concentration</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>MET</td>
<td>48</td>
<td>96</td>
</tr>
<tr>
<td>SAM</td>
<td>64.42</td>
<td>96</td>
</tr>
<tr>
<td>SAH</td>
<td>13.04</td>
<td>96</td>
</tr>
<tr>
<td>HCY</td>
<td>1.11</td>
<td>96</td>
</tr>
<tr>
<td>CH₂F</td>
<td>0.90</td>
<td>96</td>
</tr>
<tr>
<td>5mTHF</td>
<td>5.16</td>
<td>8, 9</td>
</tr>
<tr>
<td>THF</td>
<td>8.01</td>
<td>96</td>
</tr>
<tr>
<td>DHF</td>
<td>0.03</td>
<td>97, 98</td>
</tr>
<tr>
<td>CHF</td>
<td>1.12</td>
<td>96, 97</td>
</tr>
<tr>
<td>10fTHF</td>
<td>5.93</td>
<td>98, 100, 103, 104</td>
</tr>
</tbody>
</table>
Since substrate concentration dictates the velocity of reactions catalyzed by enzymes, the following differential equations were used to describe the change in substrate concentration over time:

\[
\frac{d}{dt}[5m\text{THF}] = V[\text{MTHFR}] - V[\text{MS}] + F_{in} - F_{out}
\]

\[
\frac{d}{dt}[\text{THF}] = V[\text{MS}] - V[\text{FTS}] + V[\text{PGT}] + V[\text{AICART}] + V[\text{DHFR}] - V[\text{SCHMT}] - V[\text{NE}] + V[\text{FTD}]
\]

\[
\frac{d}{dt}[\text{DHF}] = V[\text{TS}] - V[\text{DHFR}]
\]

\[
\frac{d}{dt}[\text{CH2f}] = V[\text{SHMT}] + V[\text{NE}] - V[\text{TS}] - V[\text{MTD}] - V[\text{MTHFR}]
\]

\[
\frac{d}{dt}[\text{CHF}] = V[\text{MTD}] - V[\text{MTCH}]
\]

\[
\frac{d}{dt}[10f\text{THF}] = V[\text{MTCH}] + V[\text{FTS}] - V[\text{PGT}] - V[\text{AICART}] - V[\text{FTD}]
\]

\[
\frac{d}{dt}[\text{MET}] = V[\text{BHMT}] + V[\text{MS}] - V[\text{MATI}] - V[\text{MATIII}] + \text{Metin}
\]

\[
\frac{d}{dt}[\text{SAM}] = V[\text{MATI}] + V[\text{MATIII}] - V[\text{GNMT}] - V[\text{DNMT}]
\]

\[
\frac{d}{dt}[\text{SAH}] = V[\text{GNMT}] + V[\text{DNMT}] - V[\text{SAAH}]
\]

\[
\frac{d}{dt}[\text{Hcy}] = V[\text{SAAH}] - V[\text{CBS}] - V[\text{BHMT}] - V[\text{MS}]
\]

The velocities of the reactions for each enzyme in our model are given in Table 2.3.
Table 2.3: Kinetic Parameter Values Used in Model
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Model</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AICART</strong></td>
<td></td>
<td>106-109</td>
</tr>
<tr>
<td>$K_{m,s}$ (AIRCARP)</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>$K_{m,F}$ (10f-THF)</td>
<td>5.9</td>
<td></td>
</tr>
<tr>
<td>$V_{\text{max}}$</td>
<td>45,000</td>
<td></td>
</tr>
<tr>
<td><strong>BHMT</strong></td>
<td></td>
<td>110-112</td>
</tr>
<tr>
<td>$K_{m,F}$ (HCY)</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>$K_{m,S}$ (BET)</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>$V_{\text{max}}$</td>
<td>1125</td>
<td></td>
</tr>
<tr>
<td><strong>CBS</strong></td>
<td></td>
<td>113-115</td>
</tr>
<tr>
<td>$K_m$ (HCY)</td>
<td>1000</td>
<td></td>
</tr>
<tr>
<td>$V_{\text{max}}$</td>
<td>90,000</td>
<td></td>
</tr>
<tr>
<td><strong>DHFR</strong></td>
<td></td>
<td>106, 107, 97, 116</td>
</tr>
<tr>
<td>$K_{m,s}$ (NADPH)</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>$K_{m,F}$ (DHF)</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>$V_{\text{max}}$</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td><strong>DNMT</strong></td>
<td></td>
<td>117</td>
</tr>
<tr>
<td>$K_m$</td>
<td>1.4</td>
<td></td>
</tr>
<tr>
<td>$K_i$</td>
<td>0.84</td>
<td></td>
</tr>
<tr>
<td>$V_{\text{max}}$</td>
<td>180</td>
<td></td>
</tr>
<tr>
<td><strong>FTD</strong></td>
<td></td>
<td>118</td>
</tr>
<tr>
<td>$K_{m,F}$ (10f-THF)</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>$V_{\text{max}}$</td>
<td>14,000</td>
<td></td>
</tr>
<tr>
<td><strong>FTS</strong></td>
<td></td>
<td>106, 108</td>
</tr>
<tr>
<td>$K_{m,s}$ (HCOOH)</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td>$K_{m,F}$ (THF)</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>$V_{\text{max}}$</td>
<td>2000</td>
<td></td>
</tr>
<tr>
<td><strong>GNMT</strong></td>
<td></td>
<td>119, 105, 120</td>
</tr>
<tr>
<td>$K_m$</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>$K_i$</td>
<td>10.8</td>
<td></td>
</tr>
<tr>
<td>$V_{\text{max}}$</td>
<td>288</td>
<td></td>
</tr>
<tr>
<td><strong>MAT-I</strong></td>
<td></td>
<td>121</td>
</tr>
<tr>
<td>$K_m$ (MET)</td>
<td>41</td>
<td></td>
</tr>
<tr>
<td>$V_{\text{max}}$</td>
<td>260</td>
<td></td>
</tr>
<tr>
<td><strong>MAT-III</strong></td>
<td></td>
<td>121, 122</td>
</tr>
<tr>
<td>$K_m$ (MET)</td>
<td>300</td>
<td></td>
</tr>
<tr>
<td>$V_{\text{max}}$</td>
<td>220</td>
<td></td>
</tr>
<tr>
<td><strong>MTCH (reversible)</strong></td>
<td></td>
<td>106-109</td>
</tr>
<tr>
<td>$K_{m,F1}$ (CHF)</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>$K_{m,F2}$ (10f-THF)</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>$V_{\text{max1}}$</td>
<td>800,000</td>
<td></td>
</tr>
<tr>
<td>$V_{\text{max2}}$</td>
<td>20,000</td>
<td></td>
</tr>
<tr>
<td><strong>MTHFD1 (reversible)</strong></td>
<td></td>
<td>106, 109, 97, 123</td>
</tr>
<tr>
<td>$K_{m,F1}$ (CH2F)</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Reaction/Enzyme</td>
<td>Parameters Descriptions</td>
<td>Values</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>MTHFR</td>
<td>(K_m, s(NADPH))</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>(K_m, F(5,10-CH2-THF))</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>(V_{max})</td>
<td>5000</td>
</tr>
<tr>
<td>MTR</td>
<td>(K_m, F(5mTHF))</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>(K_m, F(HCY))</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td>(V_{max})</td>
<td>500</td>
</tr>
<tr>
<td>NE of THF by 1st order mass action</td>
<td></td>
<td>129-131</td>
</tr>
<tr>
<td></td>
<td>(k_1)</td>
<td>0.15</td>
</tr>
<tr>
<td></td>
<td>(k_2)</td>
<td>12</td>
</tr>
<tr>
<td>PGT</td>
<td>(K_m, s(GAR))</td>
<td>520</td>
</tr>
<tr>
<td></td>
<td>(K_m, F(10\ell-THF))</td>
<td>4.9</td>
</tr>
<tr>
<td></td>
<td>(V_{max})</td>
<td>16,200</td>
</tr>
<tr>
<td>SAHH</td>
<td>(K_m(SAH))</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>(K_m(HCY))</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>(V_{max1})</td>
<td>5000</td>
</tr>
<tr>
<td></td>
<td>(V_{max2})</td>
<td>5000</td>
</tr>
<tr>
<td>SHMT (reversible)</td>
<td>(K_m, s1(Serine))</td>
<td>600</td>
</tr>
<tr>
<td></td>
<td>(K_m, F1(THF))</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>(K_m, s2(Glycine))</td>
<td>10,000</td>
</tr>
<tr>
<td></td>
<td>(K_m, F2(CH2-F))</td>
<td>3,200</td>
</tr>
<tr>
<td></td>
<td>(V_{max1})</td>
<td>40,000</td>
</tr>
<tr>
<td></td>
<td>(V_{max2})</td>
<td>25,000</td>
</tr>
<tr>
<td>TS</td>
<td>(K_m,dUMP)</td>
<td>6.3</td>
</tr>
<tr>
<td></td>
<td>(K_m,CH2F)</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>(V_{max})</td>
<td>5000</td>
</tr>
</tbody>
</table>

Time is given in hours, h, and concentrations are expressed in \(\mu\)M
Many of the velocity equations are assumed to behave dependently on their substrates as dictated by Michaelis-Meten kinetics (96). Thus, the rate of enzymatic activity for irreversible reactions (i.e., reactions catalyzed by MTR) is defined as

$$V_{\text{Enzyme}} = V_{\text{max}} \left[ \frac{[S]}{K_{m,s} + [S]} \right] \left[ \frac{[F]}{K_{m,f} + [F]} \right]$$

and for reversible reactions (i.e., reactions catalyzed by MTHFD1 and cSHMT),

$$V_{\text{Enzyme}} = V_{\text{max}1} \left[ \frac{[S]}{K_{m,s1} + [S]} \right] \left[ \frac{[F]}{K_{m,f1} + [F]} \right]$$
$$V_{\text{max}2} \left[ \frac{[S]}{K_{m,s2} + [S]} \right] \left[ \frac{[F]}{K_{m,f2} + [F]} \right]$$

where

- $S$ = nonfolate substrate concentration
- $F$ = folate substrate concentration

In the global folate metabolic network— and not in our highlighted subsystem of interest— the reaction between $\text{CH}_2\text{F}$ and $\text{THF}$ that is accounted for in our model is non-enzymatic. Because of this we expect the reaction to follow a mass action rate law of pseudo first-order where $k_1$ and $k_2$ are rate constants:

$$V_{NE} = k_1 [\text{THF}][\text{H}_2\text{C}=0] - k_2 [\text{CH}_2\text{F}]$$

The remaining velocity equations are presented individually, as they do not strictly adhere to general Michaelis-Menten kinetics (96); we illustrate the kinetics of each [enzyme] below as originally published by Reed et al. (96) such that when parameter values (i.e., $K_m$ and $V_{\text{max}}$) given in Table 2.3 for respective enzymes are used in the equations, the kinetics are Michaelis-Menten. Concentrations of $\text{SAM}$ and
SAH are included as regulatory methods (either activating or inhibiting an enzyme) and scaling factors are used so that the value of regulation equals 1 for our models since our initial methionine input rate \(\text{met}_{in}\) is set at 100\(\mu\text{mol/(L hr)}\). The input rate for the starting methionine level is chosen based on the work of Storch et al. (105) who found that over a 24 hour period, mean methionine levels in the human liver is approximately 100 \(\mu\text{mol/(L h)}\) after accounting for fasting and feeding states during a typical 24 hour period.

\[
V[BHMT] = a_{-0.0011}([\text{SAM}] + [\text{SAH}]) a_{0.0011}([\text{FH2}]) \left( \frac{V_{\text{max}}[\text{HCY}][\text{BET}]}{(K_m1 + \text{HCY})(K_m2 + [\text{BET}])} \right)
\]

\[
V[CBS] = \left( \frac{V_{\text{max}}[\text{HCY}]}{K_m + [\text{HCY}]} \right) \left( \frac{1.2([\text{SAM}] + [\text{SAH}])^2}{30^2 + ([\text{SAM}] + [\text{SAH}])^2} \right)
\]

\[
V[UNMT] = \frac{V_{\text{max}}[\text{SAM}]}{K_m \left( 1 + \frac{\text{SAH}}{K_I} \right) + [\text{SAM}]}
\]

\[
V[GNMT] = \left( \frac{V_{\text{max}}[\text{SAM}]}{K_m + [\text{SAM}]} \right) \left( \frac{1}{1 + \frac{\text{SAH}}{K_I}} \right) \left( \frac{4.36}{0.35 + [5\text{mTHF}]} \right)
\]

\[
V[MAT-I] = \left( \frac{V_{\text{max}}[\text{MET}]}{K_m + [\text{MET}]} \right) \left( 0.25 + (0.3)e^{-0.006[SAM]} \right)
\]

\[
V[MAT-II] = \left( \frac{V_{\text{max}}[\text{MET}]}{K_m + [\text{MET}]} \right) \left( 1 + \frac{(1.5)[\text{SAM}]^2}{K_m^2 + [\text{SAM}]^2} \right)
\]

\[
V[MTHFR] = \left( \frac{V_{\text{max}}[\text{FDP}][\text{NADPH}]}{(K_m1 + [\text{FH2}]) (K_m2 + [\text{NADPH}])} \right) \left( \frac{6.1(10)}{10 + [\text{SAM}] - [\text{FAD}]} \right)
\]
Building upon the basic folate metabolic model, we developed a mathematical model that accounts for the interactive effect of five unique SNPs in genes coding for enzymes involved in the methylation of homocysteine by MTR. The genetic effects resulting from each of the five SNPs are expressed with a scalar value that serves as a multiplier to the SNP’s corresponding enzyme velocity equation. Since a person can have one of any three possible genotypes for each of the five genetic polymorphisms (i.e., homozygous dominant, heterozygous or homozygous recessive), a total of 243 possible genetic combinations, and subsequent graphs, are created. Based on findings in the literature, the homozygous dominant genotype for each of the five SNPs is classified as the “wild type” genotype (142-147). Enzyme rate for individuals with the “wild type” genotype for a given SNP is assumed to be fully functional at 100% activity. To date, the exact rate of activity for each enzyme for a particular genotype, with the exception of MTHFR, has not been determined experimentally or published in the literature. Without such information, we approximate that the heterozygous and homozygous recessive genotypes reflect a 60% and 30% enzyme activity rate, respectively. These hypothesized reductions in enzyme activity rate for MTR, MTHFD1 and cSHMT are motivated by biological hypotheses that assume enzyme kinetics and the number of variant allele copies have a dose-response relationship: having a single variant allele corresponds to a slightly reduced enzyme activity level and having double variant allele copies corresponds to an even greater reduction in enzyme activity level. In MTHFR, the observed functional effect resulting from the \textit{MTHFR} 677 \textit{C}→\textit{T} polymorphism is 60% enzyme activity for heterozygotes (CT) and 30% in homozygote variants and 90% (AC) and 68% (CC) enzyme activity for \textit{MTHFR} 1298 \textit{A}→\textit{C} heterozygote and homozygous variant alleles, respectively (106-
Table 2.4 shows the full assignment of percentages for the SNPs.

Table 2.4: List of Functional Effects on Enzyme Activity by Polymorphism

<table>
<thead>
<tr>
<th>SNP</th>
<th>% of wild-type activity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MTHFR 677 C→T</strong></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>100</td>
</tr>
<tr>
<td>CT</td>
<td>60</td>
</tr>
<tr>
<td>TT</td>
<td>30</td>
</tr>
<tr>
<td><strong>MTHFR 1298 A→C</strong></td>
<td></td>
</tr>
<tr>
<td>AA</td>
<td>100</td>
</tr>
<tr>
<td>AC</td>
<td>90</td>
</tr>
<tr>
<td>CC</td>
<td>68</td>
</tr>
<tr>
<td><strong>MTHFD1 1958 G→A</strong></td>
<td></td>
</tr>
<tr>
<td>GG</td>
<td>100</td>
</tr>
<tr>
<td>GA</td>
<td>60</td>
</tr>
<tr>
<td>AA</td>
<td>30</td>
</tr>
<tr>
<td><strong>MTR 2756 A→G</strong></td>
<td></td>
</tr>
<tr>
<td>AA</td>
<td>100</td>
</tr>
<tr>
<td>AG</td>
<td>60</td>
</tr>
<tr>
<td>GG</td>
<td>30</td>
</tr>
<tr>
<td><strong>cSHMT 1420 C→T</strong></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>100</td>
</tr>
<tr>
<td>CT</td>
<td>60</td>
</tr>
<tr>
<td>TT</td>
<td>30</td>
</tr>
</tbody>
</table>
The remethylation of homocysteine through MTR involves several nutrient cofactors, particularly vitamin B12 and folate. To determine if nutrient levels influenced the relationship between genetic variation and homocysteine levels by effect modification, we varied the concentration of folate and vitamin B12 for each of the 243 genetic profiles. In our model, folate enters and leaves the cell as 5mTHF. The equations for $F_{in}$ and $F_{out}$, both expressed in $\mu$M/hr, is:

$$F_{in} = (\text{Steady state folate concentration})(0.0008)/24$$
$$F_{out} = \alpha([5\text{mTHF}]) , \alpha = 0.0013/h$$

According to Nijhout et al. (97), these expressions assume that the various folate pools in the body are in equilibrium and that the intracellular folate pool is depleted at the same rate as the total body folate pool which was approximated at 0.8% per day. By choosing 20 $\mu$M for steady-state folate concentration, the concentrations and values of other folate metabolites as listed in Table 2.2 stay within ranges that have been observed in studies reported in the literature. Thus, when steady state folate concentration is set at 20 $\mu$M, $F_{in} = 0.0067$. Assuming that the output from the cytosol is a first order rate process at steady state, $F_{out}$ must also equal to 0.0067. The rate constant $\alpha$ is determined to be 0.0013 since the steady state concentration of 5mTHF is 5.16 $\mu$M (Table 2.2).

The effects of a vitamin B12 and folate dose were achieved by applying a scalar multiplier of 14 to $V[MTR]$ and 100 to $V[MTHFR]$. The scalar multiplier for vitamin B12 corresponds to the findings reported in the literature of a 14-fold increase in MTR activity in liver cells supplemented with vitamin B12 (97). Epidemiological studies have shown that high dietary folate supplementation attenuates elevated homocysteine levels observed among individuals with MTHFR genetic variants (154-157). In our model, we assumed that there was a 100 fold increase in MTHFR activity
rate as a result of folate supplementation on a cellular level. Vitamin B12 and folate degradation in the body was considered to be negligible in our models because of the large half-life of vitamin B12 (400 days) and folate (100 days) (158,159). Since experimental studies have also shown that changes in MTR activity can be observed as early as two hours following vitamin B12 addition and that activity plateaus within ~24-48 hours after nutritional dosing (158), our models simulate nutrient supplementation and its effects on homocysteine concentration and steady state kinetics over a 48 hour period.

Program structure

Our model is written in Matlab and consists of four functions: ODE, RHS, V_ENZYME and COMBO_EFFECT. The ODE function is responsible for solving the differential equations and displaying the results for homocysteine and calls information from the RHS function. The RHS function defines the differential equations in terms of enzyme velocities which are subsequently defined in the V_ENZYME function. In addition to the velocity equations, the V_ENZYME function also includes associated modifiers for the effects of the SNP combinations and vitamin B12. As illustrated by Figure 2.2, the first step is where the user assigns the model parameters. The model parameters include the initial folate and non-folate substrate concentrations, folate steady state influx, vitamin B12 dosage, the profile of SNP combinations to examine, simulated time and time step. After values for all input variables have been assigned and the program is initiated, the differential equations in RHS are initially solved from t = 0 to the first time step assigned. The resulting folate substrate concentrations then replace the previously assigned initial folate substrate concentrations and the program then undergoes another iteration, using the new folate concentration. This loop continues until the assigned simulated time has been reached.
The annotated Matlab code outlining each step needed to generate our models is found in Appendix A1-A4.
Figure 2.2: Flow chart of order of program processes

User Input

Assign the new folate substrate concentration as new initial folate concentration

Initial conditions and parameters assigned

Desired SNP combination called and appropriate modifiers defined

Velocity equations evaluated using initial conditions and modifiers

Differential equations defined using values from velocity equations

Resulting folate substrate concentration determined and stored in array

Output
CHAPTER 3
FINDINGS AND CONCLUSIONS

No Supplementation

We modeled 150 scenarios for each of the 243 genotype combinations possible among our five single nucleotide polymorphisms of interest. For each of the 243 genotype profiles, we computed mean homocysteine levels (µM).

Lowest homocysteine concentration

Without any nutrient supplementation, our simulations suggest that individuals with the \textit{MTHFR} 677 \textit{TT}, \textit{MTHFR} 1298 \textit{CC}, \textit{MTHFD1} 1958 \textit{GG}, \textit{MTR} 2756 \textit{AA} and \textit{cSHMT} 1420 \textit{TT} genotypes have the lowest concentration of homocysteine (4.5µM). In this genotype, only the \textit{MTHFR} gene carries the mutated genotypes, \textit{MTHFR} 677 \textit{TT} and \textit{MTHFR} 1298 \textit{CC}, resulting in decreased function. The remaining enzymes are functioning at full capacity in this model, with the exception of cSHMT.

The consequence of this genotype appears to be that:

1. Adequate substrate is delivered to MTHFR through the optimal action of \textit{MTHFD1};
2. With no mutation observed in the \textit{MTR} 2756 \textit{A}→\textit{G} gene, MTR is able to remove all 5-methylTHF substrate, driving the reactions of the homocysteine remethylation cycle in the forward direction.
3. Because the products of MTHFR activity are quickly removed from the system, while at the same time there is a relative glut of products from \textit{MTHFD1} action, the reaction pathway for MTHFR → MTR is not reversed to favor the buildup of 5,10-methyleneTHF.

As a result, homocysteine is methylated efficiently in this scenario.
Previous single gene studies of the $MTHFR\ 677\, C\rightarrow T$ mutation have yielded equivocal results with respect to homocysteine status. The mechanism presented here may explain the lack of positive findings (i.e., elevated homocysteine levels) in the presence of the MTHFR polymorphism. It should be noted that there may be a publication bias in that negative results with this polymorphism may be discounted, as a simplistic consideration of this pathway would suggest that a polymorphism in the MTHFR gene would yield a positive result.

*Highest homocysteine concentration*

Simulation results show that among all possible 243 genotype profiles, the genotype group with the highest homocysteine concentration (11.9 µM) has the following profile: $MTHFR\ 677\, TT$, $MTHFR\ 1298\, AA$, $MTHFD1\ 1958\, AA$, $MTR\ 2756\, GG$ and $cSHMT\ 1420\, CC$.

With reduced function in MTHFD1 due to polymorphisms in $MTHFD1\ 1958\, G\rightarrow A$, the generation of 5,10-methyleneTHF is decreased, leaving only a small pool of substrate available for MTHFR to catalyze the reaction to make 5-methylTHF for MTR use. With diminished substrate levels for MTR due to polymorphisms in the $MTHFD1\ 1958\, G\rightarrow A$ and $MTHFR\ 677\, C\rightarrow T$ genes, normal MTR function is reduced, leading a build-up of homocysteine levels. The addition of a polymorphism in $MTR\ 2756\, A\rightarrow G$, causing reduced MTR activity would therefore lead to an even greater increase in homocysteine concentration, which is what we observed in our highest homocysteine group.

This result is not surprising, given that the series of mutations in the first 4 enzymes would be expected to decrease the delivery of single carbon moieties to homocysteine. This is an example of where the mutation of the MTHFR enzyme was associated with elevated homocysteine levels, in contrast with the previous model, and in synch with expectations. Taken together these examples illustrate the importance of
modeling a complete set of gene-gene interaction rather than relying on single gene studies.

The model with all the mutated polymorphisms, including \textit{MTHFR} 1298 CC yields a low homocysteine level (5.8µM). It seems at first surprising that the genotype with every possible mutation in every enzyme would result in low rather than high levels of homocysteine. However it is clear from the examples given above that it is not the presence of mutations per se that influence homocysteine levels, but rather an imbalance in the activities of MTHFR vis-à-vis the remaining enzymes. The \textit{MTHFR} 1298 CC mutation debilitates this enzyme even further, with the consequence that, relatively speaking it is more inefficient than the other enzymes. This increased inefficiency results in a pattern of relative function that is virtually the same as the pattern where only the \textit{MTHFR} gene carries the mutation. As we saw earlier, this pattern yields a low level of homocysteine.

It is clear then, that MTHFR serves as a regulator for determining whether the single-carbon units are passed either to the methionine regeneration pathway or to the thymidylate pathway. Contrary to what may be expected a priori, in this model a polymorphism in the \textit{MTHFR} gene without polymorphisms in the other enzymes, or a double polymorphism in \textit{MTHFR} coupled with polymorphisms in the other enzymes, actually leads to a better balance between substrate and product than does a lack of \textit{MTHFR} polymorphism. The explanation for this finding lies in the fact that, as the model was constructed, the MTHFR enzyme can catalyze the reaction in both directions, towards MTR and towards the thymidylate pathway. By slowing down throughput towards the MTR pathway with a MTR function high relative to MTHFR, MTHFR has to function unidirectionally, that is, towards the production of methionine.
Finally, an in vitro study directly assessing the effect of $MTHFR$ 1298 A→C on enzyme activity and thermolability concluded that the $MTHFR$ 677 C→T variant was more deleterious than the alanine variant of $MTHFR$ 1298 A→C (54), suggesting that the role of $MTHFR$ 1298 A→C on MTHFR enzyme activity is minor compared to that of $MTHFR$ 677 C→T. Overall, the evidence to date is suggests that the effect of $MTHFR$ 1298 A→C is not observed to have an effect on clinical outcomes unless there is a reduced folate status or there is also a variant allele at the 677 nucleotide ($MTHFR$ 677 C→T).

**Effect of folate supplementation**

The addition of folate into the system has no effect on homocysteine levels. Because folate acts at each point in these pathways, its levels cannot alter the balance in the pathways caused by the presence or absence of polymorphisms. The model as constructed assumes normal levels of folate in the unsupplemented condition. To see any effect of additional folate on these pathways, it would be important to run the model under folate-deficient conditions.

**Effect of vitamin B12 supplementation**

By contrast with folate, vitamin B12 occurs at only one point in the homocysteine remethylation pathway, namely at the level of MTR. In this model, vitamin B12 was designed to increase the activity of MTR. Any increase in MTR activity would be expected to accelerate the transfer of single carbon moieties to homocysteine, thus decreasing homocysteine levels. This is indeed what was found for each of the genotypes (Appendix A5). However, vitamin B12 cannot, at least in this model system, bring homocysteine levels down to normal.

**Limitations of the study**

The models in this study are constructed to simulate the effects of mutations on enzyme activity by changing enzyme kinetic rates. Except for $MTHFR$ 677 C→T, we
have assumed that mutations have a dose-response effect on enzyme availability and overall activity levels. The true effects of the MTR, cSHMT and MTHFD1 polymorphisms could be better represented in our models if such specific information on their effects were known. However, our models are created in such a way that they can be updated when new information on mutational effects become available.

Our models do not account for other linked cycles in the folate metabolic network. We have focused solely on the homocysteine remethylation pathway. The overall cellular folate concentrations of our current model may not fully predict the function of a given pathway since folate metabolism can be compartmentalized in the cell by substrate channeling through linked cycles such as those for purine or thymidylate syntheses.

We focused only on folate and vitamin B12 supplementation in our models. Our simulations assumed that no nutritional deficiency existed before supplementation. Differences in homocysteine levels among those with low nutrient status were not explored and could possibly be useful for better understanding the interaction of vitamin cofactors with their respective enzymes.

Conclusions and suggestions for further research

By examining homocysteine remethylation as a complete pathway, our mathematical models were able to capture the combined effects of linked metabolic steps on homocysteine concentration. This approach led to the key finding that having double variants for all possible polymorphisms in a pathway does not necessarily equate to the most deleterious effects. It also illustrates how pathways have built-in regulatory mechanisms that researchers might not be able to account for when taking a single candidate gene approach to studying disease outcome.

A key advantage of our simulations is that they provide for quick and easy investigation of variation in multiple inputs (i.e., gene-gene and gene-nutrient
interactions) that cannot be explored in traditional epidemiology studies. Our models can account for an unlimited number of variables and can be expanded to represent larger metabolic networks. Future research can expand upon the work presented by linking other metabolic cycles that are associated with substrates or enzymes already found in homocysteine remethylation (i.e., purine or thymidylate syntheses). Additionally, research can be done to understand how equilibrium is attained by certain genotype combinations. This could also be expanded by seeing how nutrient supplementation further modifies how steady state is achieved.

In conclusion, our mathematical modeling of homocysteine remethylation provides a new tool for investigating the effects of genetic variation and nutrient effects in one carbon metabolism. We anticipate that our model will serve as an example of how simulations can help advance the growing idea that disease treatment can be personalized by examining an individual’s unique genetic and nutritional profile.
%This program models the folate and methionine cycle.

%Modifiable settings are the following:
%(1) The set of SNP combos one wishes to model.
%This is under the ODE function under the variable
%s at line 42.

%(2) Length of time to simulate. This is under the
"tend" variable under the ODE Function at line 57.
%The units are in hours. In addition, one can also
%change how many steps the program takes to get from
%t=0 to t=tend.

%(3) Initial folate concentration. It is under the
%RHS function at line 34. For our model, the
%default is 100uM.

%(4) The rate of methionine into the system
%(to simulate met loading). This is found in
%the RHS function at line 33. Units are uM/hr.

%(5) Vitamin B12 supplementation. When there is
%supplementation, 3689uM of B12 is added into the
%system. This is done by manipulating the variable
"Vitamin_Dose" in the Enzyme function at line 21.
%Just change the value to equal 1 for B12 loading
%or 0 for no loading.

clear global s;
clf('reset');
tic

global s;
%sets s as a global variable. This variable is
%used in the "Combo_Effect" function
HCY=zeros(121,6);
THF=zeros(121,6);
%Line 35 and 36 declares two empty 101x6
%matrices named HCY and THF that the following
%code will fill with data points
HCY_col=1;
THF_col=1;

for s = (1:6);
    %This here starts the for loop that causes
    %the program to go through SNP combos 1-6.
    %"for s= (1:6) means "for s (the row of
    %vectors of the combination matrix)=1
    %through 6. To change the %set to 7-12,just
    %set s equal to "7:12" instead of "1:6".

    values0= [5.16, 8.01, 0.03, 0.90, 1.12,
              5.93, 48, 64.42, 13.04, 1.11];
    %These are the initial folate substrate
    %concentrations in uM in the order:
    %[5mTHF, THF, DHF, CH2F, CHF, 10fTHF, MET,
     SAM, SAH, HCY, HCY]

tend= 0.5;
%tend is the total time in hours that we
are modeling over

tspan=[0:tend/120:tend];
%tspan defines the time interval that
%will be modeled, as well as how many
%time steps will be taken. It is
%currently set to start at 0 hour and go
to tend hours at tend/120 time steps

options = odeset('NonNegative', [1:6]);
%Here we're setting some parameters for
%our ode solver. Note -- NonNegative
%means that whenever the solution
%approaches zero, MatLab will be extra
careful in choosing the next time step
for solving the ODE

[T,X] = ode45(@RHS,tspan,values0,options);
%This is where we call the ordinary
%differential equation (ODE) solver. The
%differential equations are called from
%the RHS function and are solved with the
%initial values, values0, as well as, 
%with respect (wrt) to the options 
%defined in line 51 The solutions are 
%then stored in the matrix X

HCY(:,HCY_col)=X(:,end);
THF(:,THF_col)=X(:,2);
%Line 86 assigns the s column vector of 
%HCY to equal the end column vector 
%(the tenth one in this case) of matrix X
HCY_col=HCY_col+1;
THF_col=HCY_col+1;
%Line 91 and 92 tell the code to record 
%the values in the next column to the 
%right

end

%In Summary, lines 42-92 define what the ODE function 
%does for each SNP %combination that is defined in the 
%"for s=" statement of line 42. In this annotated code, 
%the ODE function would run 6 times because there 
%are 1:6 combination codes that have been defined 
%by the user.

plot(T,HCY(:,1),'-or')
%Line 105 plots the 1st column vector of 
%matrix HCY.
hold all
plot(T,HCY(:,2),'-+g')
plot(T,HCY(:,3),'-*b')
plot(T,HCY(:,4),'-vc')
plot(T,HCY(:,5),'-sk')
plot(T,HCY(:,6),'-om')
hleg = legend('1','2','3','4','5','6', 
                'Location','NorthEastOutside');
%Line 114 fills out the legend of the plot.
% The key for what these numbers mean are 
% in the “Combo_Effect” function. The 
%legend has to be changed manually every 
%time to move from one set of 5 SNP 
%combinations to another.
xlabel('hours');
ylabel('[HCY]uM');

HCY
THF

% Lines 124-125 print out the values for each data point. Each column maps to a graph. Thus, the 1st column is the top graph on the legend.

str = sprintf('SetX_noB12_folate 20')

% Line 131 prints out which set is currently being modeled. It serves as a manual and internal check; each time the user runs % the simulation, the value within sprintf() % should be manually changed so when the output % is displayed in Matlab, the combination and % modifiers used are also displayed and % cross-referenced.

toc
% the tic toc command in this function directs % the program to report the total time it
function xdot = RHS(t,x)

%The RHS function is where all of the ODEs that are
%solved in the “ODE function” are defined.

Polymorphism_effect= Combo(1);
%Line 6 creates the variable “Polymorphism_effect”
%which stores the data called from combo(1).
%Combo(1) is an address that is specific to a SNP
%combination found in the “Combo_Effect” function.
%The address function is necessary when calling
%numbers from a separate function. The 1 in the
%parenthesis is just a placeholder for calling the
%data from the “Combo_Effect” function, so it can
%take on any value defined in “Combo_effect”.

Velocity = Enzyme(x,Polymorphism_effect);
%To solve the differential equations, the velocity
%values for each enzyme in %the system must be called
%in. Line 17 calls in the “V_Enzyme” function with
%the parameters x and Polymorphism_effect, where x
%is our initial folate and methionine substrate
%concentrations for the first run through of the
%folate %and methionine cycle. With each subsequent
%iteration, x changes its value to the new resulting
%concentration of folate and methionine substrates.

%SETTINGS ARE HERE

Metin = 0;
Folate_in = 100;

%In the following code, xdot refers to
%d[substrate concentration]/dt

xdot=zeros(10,1);
xdot(1) = Velocity(1) - Velocity(7) + 
    ((Folate_in*0.008)/24) - (0.0013*x(1));

xdot(2) = Velocity(7) - Velocity(5) + Velocity(3) + 
    Velocity(4) + Velocity(2) - Velocity(8) - 
    Velocity(11) + Velocity(6);

xdot(3) = Velocity(12) - Velocity(2);

xdot(4) = Velocity(8) + Velocity(11) - Velocity(12) - 
    Velocity(9) - Velocity(1);

xdot(5) = Velocity(9) - Velocity(10);

xdot(6) = Velocity(10) + Velocity(5) - Velocity(3) - 
    Velocity(4) - Velocity(6);

xdot(7) = Velocity(18) + Velocity(7) + Metin - 
    Velocity(13) - Velocity(14);

xdot(8) = Velocity(13) + Velocity(14) - Velocity(15) - 
    Velocity(17);

xdot(9) = Velocity(15) + Velocity(17) - Velocity(19);

xdot(10) = Velocity(19) - Velocity(16) - Velocity(18) - 
    Velocity(7);
A3: V_Enzyme Annotated Matlab Program

function V_Enzyme = Enzyme(x,y)
%This function defines all of the values used in
%the RHS function where the ODEs are stored. It
%also takes into account the modifying elements
%for the different SNP combinations from the
%“Combo_Effect” function. The %parameters in the
%parentheses, x and y, represent the folate
%substrate concentration and the SNP modifiers,
%respectively.

Vmax = [5000, 5000, 16200, 45000, 3000, 3300,
500, 40000, 25000, 200000, 594000,
800000, 20000,5000, 260, 220, 288,
90000, 180, 1125, 5000, 5000];

%Vmax is the Michaelis-Menten enzyme kinetic
%parameter. Time is in hours, concentrations are
%in uM and the numbers are in the order used for
%the respective enzymes in the equations below:

Vitamin_Dose = 0;
%The user can choose to modify whether or not
%supplementation by changing the value following
%“vitamin_dose=”. Vitamin_Dose can take a binary
%value of either 0 or 1 where 0 means there is
%no vitamin B12 supplementation and 1 means there
%is vitamin B12 supplementation. When there is
%vitamin B12 supplementation, 3689uM of vitamin
%B12 is added to the system. This value is
%selected for the concentration of vitamin B12
%supplementation because the DRI states that
%normal B12 absorption rate and reabsorption
%rate is 0.1% per day and 3689 uM is the
%highest amount of vitamin B12 that can be added
%to a system depleted of vitamin B12 before
%vitamin B12 retention occurs (i.e. flux in does
%not equal flux out when B12 concentration is
%greater than 3689uM).
Vitamin_Effect = 0;
% The value for Vitamin_Effect is dependent on
% the value assigned for Vitamin_Dose. If there
% is vitamin B12 supplementation (Vitamin_Dose=1)
% the literature states that the effect of the
% supplementation on MTR activity increases by a
% factor of 14 (lines 52-53). If there is no
% supplementation then Vitamin_Effect=1 because
% MTR activity stays the same as if a person has
% their steady state concentration of
% vitamin B12 (line 55).

if Vitamin_Dose == 1
    Vitamin_Effect = 14;
else
    Vitamin_Effect = 1;
End

nf_pool = [10, 2.1, 50, 1850, 468, 50, 500, 500, 20, Vitamin_Effect];

% nf_pool is a list of non-folate derived
% substrates that are present in our system. In
% our simulations, these values are kept constant
% and the constants are steady state
% concentrations in uM. Theoretically, these
% values can be modified, but they are not for the
% purposes of this model.
order: GAR, AIRCAR, NADPH, GLY, SER, BET, HCOOH, H2C=O, DUMP,
% Vitamin_B_Effect

V_Enzyme = zeros(19,1);
% Line 72 declares a matrix V_Enzyme with the
% zero matrix that has 19 rows and 1 column

% All 19 of these equations below were defined
% by Reed et al. The equations all follow
% Michaelis-Menten kinetics.
% Order:
% (1)MTHFR, (2)DHFR, (3)PGT, (4)AICART, (5)FTS,
% (6)FTD, (7)MS, (8)SHMT, (9)MTD, (10)MTCH,
%Below are the rate reactions for the enzymes listed
%in lines 80-83).

\[
V_{\text{Enzyme}(1)} = y(1) \times (V_{\text{max}(1)} \times ((\frac{\text{nF}_{\text{pool}(3)}}{16+\text{nF}_{\text{pool}(3)}}) * (\frac{x(4)}{50+x(4)}))) \times (6.1/(10+x(8)-x(9)));
\]

%Recall that "y" was our input from the SNP
%modifier (see annotation for line 1 of V_{Enzyme}
%function). Here is where "y" does the
%modification.

% y(1) defines the first element in the row
%vector
% y that is sent over to this function.

\[
V_{\text{Enzyme}(2)} = V_{\text{max}(2)} * ((\frac{\text{nF}_{\text{pool}(3)}}{4+\text{nF}_{\text{pool}(3)}})) \times ((\frac{x(3)}{0.5+x(3)}));
\]

\[
V_{\text{Enzyme}(3)} = V_{\text{max}(3)} * ((\frac{\text{nF}_{\text{pool}(1)}}{520+\text{nF}_{\text{pool}(1)}}) * (\frac{x(6)}{4.9+x(6)}));
\]

\[
V_{\text{Enzyme}(4)} = V_{\text{max}(4)} * ((\frac{\text{nF}_{\text{pool}(2)}}{100+\text{nF}_{\text{pool}(2)}}) * (\frac{x(6)}{5.9+x(6)}));
\]

\[
V_{\text{Enzyme}(5)} = V_{\text{max}(5)} * ((\frac{\text{nF}_{\text{pool}(7)}}{43+nF_{pool}(7)}) * (\frac{x(2)}{10+x(2)}));
\]

\[
V_{\text{Enzyme}(6)} = V_{\text{max}(6)} * (\frac{x(6)}{0.9+x(6)}));
\]

\[
V_{\text{Enzyme}(7)} = \text{Vitamin\_Effect} \times y(3) \times (V_{\text{max}(7)} * (\frac{x(10)}{0.1+x(10)}) * (\frac{x(1)}{25+x(1)}));
\]

\[
V_{\text{Enzyme}(8)} = y(4) \times ((V_{\text{max}(8)} * ((\text{nF}_{\text{pool}(5)}/(600+nF_{pool}(5)))) * (\frac{x(2)}{50+x(2)})) - (V_{\text{max}(9)} * ((\text{nF}_{\text{pool}(4)}/(10000+nF_{pool}(4)))) * (\frac{x(4)}{3200+x(4)}));
\]

\[
V_{\text{Enzyme}(9)} = y(2) \times ((V_{\text{max}(10)} * ((\text{nF}_{\text{pool}(5)}/(2+x(4)))) - (V_{\text{max}(11)} * (x(5)/(10+x(5)))));
\]

\[
V_{\text{Enzyme}(10)} = (V_{\text{max}(12)} * ((x(5)/(250+x(5))))) - (V_{\text{max}(13)} * (x(6)/(100+x(6))));
\]

\[
V_{\text{Enzyme}(11)} = 0.15 \times x(2) \times nF_{pool}(7) - 12 \times x(4);
\]

\[
V_{\text{Enzyme}(12)} = V_{\text{max}(14)} * ((\text{nF}_{\text{pool}(9)/})
\]
\( (6.3 + \text{nf\_pool}(9)) \times \left( \frac{x(4)}{14 + x(4)} \right) \); \\
\( V_{\text{Enzyme}}(13) = V_{\text{max}}(15) \times \left( \frac{x(7)}{41 + x(7)} \right) \times \\
(0.23 + 0.8 \times \exp(-0.026 \times x(8))) \); \\
\( V_{\text{Enzyme}}(14) = V_{\text{max}}(16) \times \left( \frac{x(7)^{1.21}}{300 + (x(7)^{1.21})} \right) \times (1 + (7.2 \times (x(8)^{2}))) / \\
((360^{2} + (x(8)^{2}))) \); \\
\( V_{\text{Enzyme}}(15) = V_{\text{max}}(17) \times \left( \frac{x(8)}{63 + x(8)} \right) \\
\times (1/(1 + (x(9)/10.8))) \times (4.38/ \\
(0.35 + x(1))) \); \\
\( V_{\text{Enzyme}}(16) = V_{\text{max}}(18) \times \left( \frac{x(10)}{1000 + x(10)} \right) \times \\
(((1.2 \times x(8)) + (x(9)^{2}))/((30^{2}) + \\
(x(8) + x(9)^{2}))) \); \\
\( V_{\text{Enzyme}}(17) = V_{\text{max}}(19) \times \left( \frac{x(8)}{1.4 \times (1 + (x(9)/ \\
1.4) + x(8)))} \right) \); \\
\( V_{\text{Enzyme}}(18) = \exp(-0.0021 \times (x(8) + x(9))) \times (0.0021 \times \\
77.2) \times V_{\text{max}}(20) \times \left( x(10) \times \text{nf\_pool}(6) \right) \times \\
/((12 + x(10)) \times (100 \times \text{nf\_pool}(6))) \); \\
\( V_{\text{Enzyme}}(19) = V_{\text{max}}(21) \times (x(9)/(10 + x(9))) - V_{\text{max}}(22) \\
\times (x(10)/(1 + x(10))) \); \\
\( V_{\text{Enzyme}} \);
function combo_effect = Combo(z)
%This function serves two purposes, to generate all
%of the SNP combinations and to assign the
%respective modifiers

global s;
%Line 6 refers to the global variable, s, that
%is originally defined in the %"ODE" function.

n=s;
%Line 10 declares and defines a variable, n, to
%equal whatever s is at the time. So first run
%through, s=n=1. Second run through, s=n=2, etc.

MTHFR = [1 2 3 4 5 6];
%Line 15 refers to the C667T polymorphism.
%Number 1 = Homozygous dominant CC,
%2 = Heterozygous CT, 3 = Homozygous recessive TT.
%4-6 refer to the A1298C
%polymorphism. Number 4 = Homozygous dominant AA,
%5 = Heterozygous AC, 6 = Homozygous recessive CC.

MTD = [7 8 9];
%Number 1 = Homozygous dominant GG,
%2 = Heterozygous GA, 3 = Homozygous recessive AA.

MS = [10 11 12];
%Number 1 = Homozygous dominant AA,
%2 = Heterozygous AG, 3 = Homozygous recessive GG.

SHMT = [13 14 15];
%Number 1 = Homozygous dominant CC,
%2 = Heterozygous CT, 3 = Homozygous recessive TT.

sets = {MTHFR, MTD, MS, SHMT};
%Line 35 combines all of the genotypes
%mentioned in lines 23-33 into a single matrix

[w x y z] = ndgrid(sets(:));
%Line 39 uses the ndgrid command to generate
%all the possible combinations of SNPs

combo = [w(:) x(:) y(:) z(:)];
%Line 43 defines matrix "combo" to be the
%result of the line 31

selected_combo = combo (n,:);
%Line 47 selects the row vector n in the matrix
%"combo". Recall that n is equal to the global
%variable s. Currently, for every cycle, s increases
%by 1, thus for every cycle, the code will select
%the next SNP combo in the %matrix "combo". In other
%words, the code will move down to the next row in
%the matrix.

%MTHFR Polymorphisms
if selected_combo(1) == 1
    selected_combo(1) = 1;
elseif selected_combo(1) == 2
    selected_combo(1) = 0.6;
elseif selected_combo(1) == 3
    selected_combo(1) = 0.3;
elseif selected_combo(1) == 4
    selected_combo(1) = 1;
elseif selected_combo(1) == 5
    selected_combo(1) = 0.9;
else
    selected_combo(1) = 0.68;
end
%In this if-statement, the appropriate modifiers are
%applied to the corresponding SNP combination.
%In matrix "combo", the entire first column refers
%to MTHFR. For example, if a row, say [2 8 11 15],
%2 would refer to the polymorphism of MTHFR c667t.
%Specifically the heterozygousgenotype MTHFR 677 CT.
%Following the code from line 52, the program checks
%if the first element in the selected SNP combo is
%equal to 1. If element is equal to 1, then the
%value remains 1. Else, if the first element is
%equal to 2, then the first element is changed from
%2 to 0.6. This continues down the entire
%if-statement. These decimal numbers represent...
% percent change in activity of the corresponding enzyme due to the polymorphism. In this example, % the heterozygous MTHFR 677 CT polymorphism % causes MTHFR to perform at 60% of its optimal % efficiency (value is literature based).

% MTD Polymorphisms
if selected_combo(2) == 7
    selected_combo(2) = 1;
    elseif selected_combo(2) == 8
        selected_combo(2) = 0.6;
    else
        selected_combo(2) = 0.3;
    % where selected_combo(2) == 9
end

% MS Polymorphisms
if selected_combo(3) == 10
    selected_combo(3) = 1;
    elseif selected_combo(3) == 11
        selected_combo(3) = 0.6;
    else
        selected_combo(3) = 0.3;
    % where selected_combo(3) == 12
end

% SHMT Polymorphisms
if selected_combo(4) == 13
    selected_combo(4) = 1;
    elseif selected_combo(4) == 14
        selected_combo(4) = 0.6;
    else
        selected_combo(4) = 0.3;
    % where selected_combo(4) == 15
end

combo_effect = selected_combo;

% [A,B] = size(combo)
% line 122, commented out, gives the size of matrix combo.
A5: Simulation Results for All Polymorphism and Nutrients

The following graphs depict the simulation results from running the homocysteine remethylation pathway model described in Chapter 2 for all 243 possible genotypes. The graphs reflect the change in homocysteine concentration over a two day period with no supplementation (red), folate only supplementation (blue), vitamin B12 only supplementation (green) and both folate and vitamin B12 supplementation (black).
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CC

MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CC
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CC

MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CC
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CC

MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CC
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CC

MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC

MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC

MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC

MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC

MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CC
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC

MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC

MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC

MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC

MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CC
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC

MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC

MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC

MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC

MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC

MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC

MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC

MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC

MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CC

MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC

MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC

MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC

MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC

MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CC
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC

MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC

MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC

MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC

MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CC

MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC

MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC

MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC

MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC

MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CC
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC

MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC

MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC

MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC

MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CC

MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT

MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT

MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT

MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT

MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 CT
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT

MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT

MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT

MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT

MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 CT

MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT

MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT

MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT

MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT

MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 CT
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT

MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT

MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT

MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT

MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 CT

MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT

MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT

MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT

MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT

MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 CT
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT

MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT

MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT

MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT

MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 CT

MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CT
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CT

MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CT
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CT

MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CT
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CT

MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 CT
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT

MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT

MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT

MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT

MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 CT

MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT

MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT

MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT

MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT

MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 CT
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT

MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT

MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT

MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT

MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AA, cSHMT 1420 TT

MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT

MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT

MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT

MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AA, cSHMT 1420 TT
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT

MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT

MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT

MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT

MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AA, cSHMT 1420 TT

MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT

MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT

MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT

MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT

MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 AG, cSHMT 1420 TT
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT

MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT

MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT

MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT

MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 AG, cSHMT 1420 TT

MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT

MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT

MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT

MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT

MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 AG, cSHMT 1420 TT
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT

MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT

MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT

MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT

MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GG, MTR 2756 GG, cSHMT 1420 TT

MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT
MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT

MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT
MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT

MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT
MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT

MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT
MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT

MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 GA, MTR 2756 GG, cSHMT 1420 TT
MTHFR 677 CC, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT

MTHFR 677 CC, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT
MTHFR 677 CC, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT

MTHFR 677 CT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT
MTHFR 677 CT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT

MTHFR 677 CT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT
MTHFR 677 TT, MTHFR 1298 AA, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT

MTHFR 677 TT, MTHFR 1298 AC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT
MTHFR 677 TT, MTHFR 1298 CC, MTHFD1 1958 AA, MTR 2756 GG, cSHMT 1420 TT
REFERENCES


53. Harmon D, et al. The common 'thermolabile' variant of methylenetetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM, 1996. 89: p. 571-7


81. The HAPMAP Project


106. de Bree A, Verschuren WM, Bjorke-Monsen AL, van der Put NM, Heil SG, Trijbels FJ, Blom HJ. Effect of the methylenetetrahydrofolate reductase 677C→T


124. Bjarnason GA, Jordan RC, Wood PA, Li Q, Lincoln DW, Sothern RB, Hrushesky WJ, Ben-David Y. Circadian expression of clock genes in human oral


142. Chen J, Stampfer MJ, Ma J, Selhub J, Malinow MR, Hennekens CH, Hunter DJ. Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine


152. Stern LL, Mason JB, Selhub J, Choi SW. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol Biomarkers Prev 2000. 9: p.849–53